The number of cases in contracted medical institution of tella

Clinical experiences with dendritic cell vaccine therapy in approximately 12,200 patients

One of Tella’s cancer vaccines, the dendritic cell vaccine therapy, has been provided to approximately 12,200 patients in 28 medical institutions around Japan, as of the end of december, 2019.
In addition, patient data were analyzed in collaboration with not only doctors from our partner medical institutions but also those from university hospitals to provide more beneficial therapies to patients.

Clinical Result

In the journal of American Pancreatic Association "Pancreas", the effects of dendritic cell vaccines with anti-cancer agents were observed in about 35% (17/49) patients of advanced panceratic cancer (see below).